Brossart et al. studied patients with advanced breast and ovarian cancer vaccinated with autologous DCs pulsed with HER-2/neu- or MUC1-derived peptides [27], and was one of the earliest to show that vaccination with DCs pulsed with a single tumor antigen may induce immunologic responses in patients with ovarian cancer. Here, MUC1 is linked to ovarian cancer.